US6383814B1
(en)
|
1994-12-09 |
2002-05-07 |
Genzyme Corporation |
Cationic amphiphiles for intracellular delivery of therapeutic molecules
|
US5939401A
(en)
*
|
1994-12-09 |
1999-08-17 |
Genzyme Corporation |
Cationic amphiphile compositions for intracellular delivery of therapeutic molecules
|
US6331524B1
(en)
|
1994-12-09 |
2001-12-18 |
Genzyme Corporation |
Organ-specific targeting of cationic amphiphile / DNA complexes for gene therapy
|
US5948767A
(en)
*
|
1994-12-09 |
1999-09-07 |
Genzyme Corporation |
Cationic amphiphile/DNA complexes
|
FR2730637B1
(fr)
|
1995-02-17 |
1997-03-28 |
Rhone Poulenc Rorer Sa |
Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
|
AUPN741696A0
(en)
*
|
1996-01-05 |
1996-01-25 |
Commonwealth Scientific And Industrial Research Organisation |
Delivery of nucleic acids ii
|
FR2756491B1
(fr)
*
|
1996-11-29 |
1999-01-08 |
Rhone Poulenc Rorer Sa |
Composition transfectante utile en therapie genique associan t a un virus recombinant incorporant un acide nucleique exog ene, un agent de transfection non viral et non plasmidique
|
DE19637043A1
(de)
*
|
1996-09-12 |
1998-03-19 |
Boehringer Mannheim Gmbh |
Neue Aminoalkoholderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel und Reagenzien
|
US7097854B2
(en)
|
1996-09-12 |
2006-08-29 |
Medigene Oncology Gmbh |
Amino alcohol derivatives, process for their production and pharmaceutical preparations and reagents containing these compounds
|
FR2754272B1
(fr)
*
|
1996-10-08 |
1998-11-13 |
Rhone Poulenc Rorer Sa |
Procede de preparation de compositions pour le transfert d'acides nucleiques
|
US7008776B1
(en)
|
1996-12-06 |
2006-03-07 |
Aventis Pharmaceuticals Inc. |
Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol
|
US6884430B1
(en)
*
|
1997-02-10 |
2005-04-26 |
Aventis Pharma S.A. |
Formulation of stabilized cationic transfection agent(s) /nucleic acid particles
|
US6638502B1
(en)
|
1997-04-28 |
2003-10-28 |
Gencell Sas |
Adenovirus-mediated intratumoral delivery of an angiogenesis antagonist for the treatment of tumors
|
FR2763943B1
(fr)
*
|
1997-05-28 |
1999-07-09 |
Rhone Poulenc Rorer Sa |
Composes, leur preparation et leur utilisation pour le transfert d'acides nucleiques dans les cellules
|
US6875606B1
(en)
|
1997-10-23 |
2005-04-05 |
The United States Of America As Represented By The Department Of Veterans Affairs |
Human α-7 nicotinic receptor promoter
|
IL137247A0
(en)
|
1998-01-30 |
2001-07-24 |
Aventis Pharma Sa |
Transfecting compositions sensitive to reducing conditions, pharmaceutical compositions containing them, and their applications
|
FR2777017B1
(fr)
*
|
1998-04-02 |
2002-08-23 |
Rhone Poulenc Rorer Sa |
Nouveaux agents de transfert d'acides nucleiques, compositions les contenant et leurs applications
|
BR9909350A
(pt)
*
|
1998-04-02 |
2000-12-12 |
Aventis Pharma Sa |
Compostos, composição, utilização de um composto, e, processos para preparação dos compostos, para transferência de ácido nucleicos para as células e para tratamento de doenças por meio de administração de um ácido nucleico
|
WO1999052858A2
(en)
|
1998-04-08 |
1999-10-21 |
Celltech Therapeutics Limited |
Lipids
|
US6225456B1
(en)
|
1998-05-07 |
2001-05-01 |
University Technololy Corporation |
Ras suppressor SUR-5
|
US6506889B1
(en)
|
1998-05-19 |
2003-01-14 |
University Technology Corporation |
Ras suppressor SUR-8 and related compositions and methods
|
US6441156B1
(en)
*
|
1998-12-30 |
2002-08-27 |
The United States Of America As Represented By The Department Of Health And Human Services |
Calcium channel compositions and methods of use thereof
|
ES2288472T3
(es)
*
|
1999-04-26 |
2008-01-16 |
Ucb Pharma, S.A. |
Lipidos bipolares y su uso para la liberacion de sustancias bioactivas.
|
GB9918670D0
(en)
|
1999-08-06 |
1999-10-13 |
Celltech Therapeutics Ltd |
Biological product
|
WO2001040254A1
(fr)
*
|
1999-12-02 |
2001-06-07 |
Tomohiko Ohwada |
Reactifs pour transfert de genes
|
EP1276500B1
(en)
|
2000-03-13 |
2011-06-08 |
Cornell Research Foundation, Inc. |
Blocking leukocyte emigration and inflammation by interfering with cd99/hec2
|
US20040033600A1
(en)
|
2001-03-21 |
2004-02-19 |
Palli Subba Reddy |
Ecdysone receptor-based inducible gene expression system
|
GB0018307D0
(en)
|
2000-07-26 |
2000-09-13 |
Aventis Pharm Prod Inc |
Polypeptides
|
EP1272526A4
(en)
|
2000-04-13 |
2004-10-13 |
Univ Rockefeller |
REINFORCING ANTIBODY-IMMUNE RESPONSE
|
KR100373844B1
(ko)
*
|
2000-09-21 |
2003-02-26 |
굿젠 주식회사 |
유전자 및 생물학적 활성 약물 전달용 양이온성 지질과이의 제조방법
|
KR100373845B1
(ko)
*
|
2000-09-21 |
2003-02-26 |
굿젠 주식회사 |
유전자 및 생물학적 활성 약물 전달용 양이온성 지질과이의 제조방법
|
US8105825B2
(en)
|
2000-10-03 |
2012-01-31 |
Intrexon Corporation |
Multiple inducible gene regulation system
|
US20020091242A1
(en)
|
2000-10-11 |
2002-07-11 |
Michel Bessodes |
Acid-sensitive compounds, their preparation and uses
|
IL155726A0
(en)
|
2000-12-28 |
2003-11-23 |
Wyeth Corp |
Recombinant protective protein from streptococcus pneumoniae
|
JP4328094B2
(ja)
|
2001-02-20 |
2009-09-09 |
イントレクソン・コーポレイション |
新規置換突然変異体受容体および核受容体−ベースの誘導性遺伝子発現システムにおけるその使用
|
JP4955905B2
(ja)
|
2001-02-20 |
2012-06-20 |
イントレキソン コーポレーション |
キメラレチノイドx受容体および新規エクジソン受容体−ベースの誘導性遺伝子発現システムにおけるそれらの使用
|
ES2385598T3
(es)
|
2001-02-20 |
2012-07-27 |
Intrexon Corporation |
Sistema novedoso de expresión génica inducible basado en el receptor de ecdisona/receptor X retinoide de invertebrado
|
JP4994563B2
(ja)
|
2001-02-20 |
2012-08-08 |
イントレキソン コーポレーション |
新規置換突然変異体受容体および核受容体−ベースの誘導性遺伝子発現システムにおけるその使用
|
CA2441476A1
(en)
|
2001-03-02 |
2002-09-12 |
The Rockefeller University |
Recombinant hybrid allergen constructs with reduced allergenicity that retain immunogenicity of the natural allergen
|
JP2005507247A
(ja)
|
2001-09-26 |
2005-03-17 |
レオジーン・ホールディングス,インコーポレーテッド |
コナジラミエクジソン受容体核酸、ポリペプチド、およびそれらの使用
|
US7563879B2
(en)
|
2001-09-26 |
2009-07-21 |
Intrexon Corporation |
Leafhopper ecdysone receptor nucleic acids, polypeptides, and uses thereof
|
US20040023910A1
(en)
*
|
2001-09-28 |
2004-02-05 |
Zhiming Zhang |
Use of cyr61 in the treatment and diagnosis of human uterine leiomyomas
|
MX339524B
(es)
|
2001-10-11 |
2016-05-30 |
Wyeth Corp |
Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
|
PT1479985T
(pt)
|
2002-01-17 |
2017-08-03 |
Alfa Laval Corp Ab |
Evaporador submerso compreendendo um permutador de calor de placas e um compartimento cilíndrico onde está disposto o permutador de calor de placas
|
EP2316921B1
(en)
|
2002-05-24 |
2014-05-14 |
Merck Sharp & Dohme Corp. |
Neutralizing human anti-IGFR antibody
|
US7375093B2
(en)
|
2002-07-05 |
2008-05-20 |
Intrexon Corporation |
Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
|
US7785608B2
(en)
|
2002-08-30 |
2010-08-31 |
Wyeth Holdings Corporation |
Immunogenic compositions for the prevention and treatment of meningococcal disease
|
US7304161B2
(en)
*
|
2003-02-10 |
2007-12-04 |
Intrexon Corporation |
Diaclhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex
|
US7456315B2
(en)
|
2003-02-28 |
2008-11-25 |
Intrexon Corporation |
Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
|
US7432057B2
(en)
|
2004-01-30 |
2008-10-07 |
Michigan State University |
Genetic test for PSE-susceptible turkeys
|
EP2267458A3
(en)
|
2004-04-20 |
2011-04-06 |
Galapagos N.V. |
Methods, compositions and compound assays for inhibiting amyloid-beta protein production
|
WO2005103716A2
(en)
|
2004-04-27 |
2005-11-03 |
Galapagos N.V. |
Methods, agents, and compound screening assays for inducing differentiation of undifferentiated mammalian cells into osteoblasts
|
US7935510B2
(en)
|
2004-04-30 |
2011-05-03 |
Intrexon Corporation |
Mutant receptors and their use in a nuclear receptor-based inducible gene expression system
|
EP1773997B1
(en)
|
2004-06-14 |
2011-11-23 |
Galapagos N.V. |
Methods for identification, and compounds useful for the treatment of degenerative & inflammatory diseases
|
WO2005124342A2
(en)
|
2004-06-21 |
2005-12-29 |
Galapagos N.V. |
Methods and means for treatment of osteoarthritis
|
US7604798B2
(en)
|
2004-07-15 |
2009-10-20 |
Northwestern University |
Methods and compositions for importing nucleic acids into cell nuclei
|
ATE527281T1
(de)
|
2004-07-16 |
2011-10-15 |
Us Gov Health & Human Serv |
Impfstoffe gegen aids umfassend cmv/r nucleinsäurekonstrukte
|
US7485468B2
(en)
|
2004-10-15 |
2009-02-03 |
Galapagos Bv |
Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases
|
US9034650B2
(en)
|
2005-02-02 |
2015-05-19 |
Intrexon Corporation |
Site-specific serine recombinases and methods of their use
|
US20060211004A1
(en)
|
2005-02-15 |
2006-09-21 |
Ilsley Diane D |
Methods and compositions for determining non-specific cytotoxicity of a transfection agent
|
CN101437539B
(zh)
|
2005-07-05 |
2013-10-02 |
康奈尔研究基金会(有限公司) |
通过干扰cd99l2阻断白细胞迁出和炎症
|
WO2007028147A2
(en)
|
2005-09-01 |
2007-03-08 |
Philadelphia Health & Education Corporation D.B.A. Drexel University College Of Medicin |
Identification of a prostatic intraepithelial neoplasia (pin)-specific gene and protein (pin-1) useful as a diagnostic treatment for prostate cancer
|
KR101137454B1
(ko)
|
2006-07-28 |
2012-04-20 |
사노피 |
종양 치료를 위한 조성물 및 방법
|
EP2068921B1
(en)
|
2006-10-19 |
2014-07-09 |
CSL Limited |
High affinity antibody antagonists of interleukin-13 receptor alpha 1
|
US8613925B2
(en)
|
2006-10-19 |
2013-12-24 |
Csl Limited |
Anti-IL-13Rα1 antibodies and their uses thereof
|
CA2673622A1
(en)
*
|
2006-12-22 |
2008-07-03 |
Imuthes Limited |
Lipid
|
AR064642A1
(es)
|
2006-12-22 |
2009-04-15 |
Wyeth Corp |
Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
|
EP2167458B1
(en)
|
2007-05-29 |
2018-03-14 |
Intrexon Corporation |
Chiral diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
|
EP2162747B1
(en)
|
2007-06-20 |
2014-04-30 |
Galapagos N.V. |
Molecular targets and methods to identify compounds for treating bone and joint degenerative diseases
|
US20090069266A1
(en)
|
2007-06-27 |
2009-03-12 |
Northwestern University |
Methods and compositions for nucleic acid transfer into cells
|
KR20100049084A
(ko)
|
2007-08-23 |
2010-05-11 |
인트렉손 코포레이션 |
질병 진단을 위한 방법 및 조성물
|
CA2698460C
(en)
*
|
2007-09-17 |
2015-11-24 |
Rohm And Haas Company |
Compositions and methods for the modification of physiological responses in plants
|
KR101666228B1
(ko)
|
2007-09-28 |
2016-10-13 |
인트렉손 코포레이션 |
생물치료학적 분자를 발현시키기 위한 치료학적 유전자-스위치 작제물 및 생물반응기, 및 이의 용도
|
ES2636460T3
(es)
|
2007-10-08 |
2017-10-05 |
Intrexon Corporation |
Células dendríticas modificadas por ingeniería y usos para el tratamiento del cáncer
|
WO2010026537A1
(en)
|
2008-09-05 |
2010-03-11 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Novel multimodular assembly useful for intracellular delivery
|
CA2736425A1
(en)
|
2008-09-11 |
2010-03-18 |
Galapagos Nv |
Method for identifying compounds useful for increasing the functional activity and cell surface expression of cf-associated mutant cystic fibrosis transmembrane conductance regulator
|
KR20110081282A
(ko)
|
2008-11-05 |
2011-07-13 |
와이어쓰 엘엘씨 |
베타―용혈성 연쇄구균 (bhs) 질환의 예방을 위한 다성분 면역원성 조성물
|
WO2010096561A1
(en)
|
2009-02-18 |
2010-08-26 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Synthetic hiv/siv gag proteins and uses thereof
|
WO2010094734A2
(en)
|
2009-02-19 |
2010-08-26 |
Biofocus Dpi B.V. |
Methods for identifying and compounds useful for the diagnosis and treatment of diseases involving inflammation
|
JP2012518181A
(ja)
|
2009-02-19 |
2012-08-09 |
ガラパゴス・ナムローゼ・フェンノートシャップ |
炎症を包含する疾患の診断及び治療に有用な同定方法及び化合物
|
EP2398481A2
(en)
|
2009-02-19 |
2011-12-28 |
Galapagos N.V. |
Methods for identifying and compounds useful for the diagnosis and treatment of diseases involving inflammation
|
EP2414830A2
(en)
|
2009-03-31 |
2012-02-08 |
Robert Zimmermann |
Modulation of adipose triglyceride lipase for prevention and treatment of cachexia, loss of weight and muscle atrophy and methods of screening therefor
|
WO2010112569A1
(en)
|
2009-03-31 |
2010-10-07 |
Robert Zimmermann |
Modulation of adipose triglyceride lipase for prevention and treatment of cachexia, loss of weight and muscle atrophy and methods of screening therefor
|
US8663930B2
(en)
|
2009-04-01 |
2014-03-04 |
Galapagos Nv |
Methods and means for treatment of osteoarthritis
|
AU2010237046B2
(en)
|
2009-04-17 |
2015-06-04 |
New York University |
Peptides targeting TNF family receptors and antagonizing TNF action, compositions, methods and uses thereof
|
WO2011015573A1
(en)
|
2009-08-03 |
2011-02-10 |
Galapagos Nv |
Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases
|
WO2011015572A1
(en)
|
2009-08-03 |
2011-02-10 |
Galapagos Nv |
Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases
|
US9186370B2
(en)
|
2010-03-19 |
2015-11-17 |
University Of South Alabama |
Methods and compositions for the treatment of cancer
|
AU2011232435B2
(en)
|
2010-03-23 |
2016-01-28 |
Intrexon Corporation |
Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof
|
ES2850973T3
(es)
|
2010-08-23 |
2021-09-01 |
Wyeth Llc |
Formulaciones estables de antígenos rLP2086 de Neisseria meningitidis
|
ES2728282T3
(es)
|
2010-09-10 |
2019-10-23 |
Wyeth Llc |
Variantes no lipidadas de antígenos ORF2086 de Neisseria meningitidis
|
US9109219B2
(en)
|
2010-12-09 |
2015-08-18 |
Institut Pasteur |
MGMT-based method for obtaining high yields of recombinant protein expression
|
EP2492279A1
(en)
|
2011-02-25 |
2012-08-29 |
Laboratorios Del. Dr. Esteve, S.A. |
Rapid immunogen selection method using lentiviral display
|
AU2012225749B2
(en)
|
2011-03-04 |
2015-01-22 |
Intrexon Corporation |
Vectors conditionally expressing protein
|
WO2012135696A2
(en)
|
2011-04-01 |
2012-10-04 |
University Of South Alabama |
Methods and compositions for the diagnosis, classification, and treatment of cancer
|
EP2546358A1
(en)
|
2011-07-15 |
2013-01-16 |
Laboratorios Del. Dr. Esteve, S.A. |
Methods and reagents for efficient control of HIV progression
|
PT2760463T
(pt)
|
2011-09-20 |
2019-02-27 |
Univ North Carolina Chapel Hill |
Regulação de canais de sódio por proteínas plunc
|
WO2013053765A1
(en)
|
2011-10-11 |
2013-04-18 |
Proyecto De Biomedicina Cima, S.L. |
A non-human animal model of mucosa-associated lymphoid tissue (malt) lymphoma
|
CA2856742A1
(en)
|
2011-12-07 |
2013-06-13 |
Alnylam Pharmaceuticals, Inc. |
Biodegradable lipids for the delivery of active agents
|
AU2012350229B2
(en)
|
2011-12-09 |
2018-03-22 |
Institut Pasteur |
Multiplex immuno screening assay
|
WO2013103401A1
(en)
|
2012-01-06 |
2013-07-11 |
University Of South Alabama |
Methods and compositions for the treatment of cancer
|
CZ303963B6
(cs)
*
|
2012-01-13 |
2013-07-17 |
Ústav organické chemie a biochemie Akademie ved CR, v.v.i. |
Lipopolyaminy sperminového typu pro konstrukci liposomálních transfekcních systému
|
JP5925342B2
(ja)
|
2012-03-09 |
2016-05-25 |
ファイザー・インク |
髄膜炎菌(Neisseriameningitidis)組成物およびその方法
|
SA115360586B1
(ar)
|
2012-03-09 |
2017-04-12 |
فايزر انك |
تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
|
EP2698377A1
(en)
|
2012-08-17 |
2014-02-19 |
Laboratorios Del. Dr. Esteve, S.A. |
Enhanced rapid immunogen selection method for HIV gp120 variants
|
WO2014107739A1
(en)
|
2013-01-07 |
2014-07-10 |
Eleven Biotherapeutics, Inc. |
Antibodies against pcsk9
|
US9802987B2
(en)
|
2013-03-08 |
2017-10-31 |
Pfizer Inc. |
Immunogenic fusion polypeptides
|
US10981961B2
(en)
|
2013-03-11 |
2021-04-20 |
University Of Florida Research Foundation, Incorporated |
Delivery of card protein as therapy for occular inflammation
|
WO2014139884A2
(en)
|
2013-03-14 |
2014-09-18 |
Galapagos Nv |
Molecular targets and compounds, and methods to identify the same, useful in the treatment of fibrosis
|
WO2014139885A2
(en)
|
2013-03-14 |
2014-09-18 |
Galapagos Nv |
Molecular targets and compounds, and methods to identify the same, useful in the treatment of diseases associated with epithelial mesenchymal transition
|
JP6437467B2
(ja)
|
2013-03-14 |
2018-12-19 |
ガラパゴス・ナムローゼ・フェンノートシャップGalapagos N.V. |
線維化疾患治療において有用な分子標的及び化合物、並びにこれらの同定方法
|
SG11201506875YA
(en)
|
2013-03-15 |
2015-09-29 |
Intrexon Corp |
Boron-containing diacylhydrazines
|
US20160130585A1
(en)
|
2013-05-28 |
2016-05-12 |
The Johns Hopkins University |
Aptamers for the treatment of sickle cell disease
|
BR112016004463A2
(pt)
|
2013-09-08 |
2017-10-17 |
Pfizer |
composições de neisseria meningitidis e métodos das mesmas
|
EP3107939B1
(en)
|
2014-02-19 |
2020-06-17 |
University of Florida Research Foundation, Inc. |
Delivery of nrf2 as therapy for protection against reactive oxygen species
|
KR101605421B1
(ko)
|
2014-03-05 |
2016-03-23 |
국립암센터 |
B 세포 림프종 세포를 특이적으로 인지하는 단일클론항체 및 이의 용도
|
CA2953341C
(en)
|
2014-06-25 |
2023-01-24 |
Acuitas Therapeutics Inc. |
Lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
CA2961738A1
(en)
|
2014-09-17 |
2016-03-24 |
Intrexon Corporation |
Boron-containing diacylhydrazine compounds
|
US10888611B2
(en)
|
2015-02-19 |
2021-01-12 |
Pfizer Inc. |
Neisseria meningitidis compositions and methods thereof
|
TW201710503A
(zh)
|
2015-06-12 |
2017-03-16 |
長庚醫療財團法人林口長庚紀念醫院 |
新穎多核苷酸、載體、醫藥組成物以及其用途
|
US10221127B2
(en)
|
2015-06-29 |
2019-03-05 |
Acuitas Therapeutics, Inc. |
Lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
AU2016334401A1
(en)
|
2015-10-10 |
2018-04-26 |
Intrexon Corporation |
Improved therapeutic control of proteolytically sensitive, destabilized forms of interleukin-12
|
RS63986B1
(sr)
|
2015-10-28 |
2023-03-31 |
Acuitas Therapeutics Inc |
Novi lipidi i lipidne formulacije nanočestica za isporuku nukleinskih kiselina
|
CA3042706A1
(en)
|
2016-11-09 |
2018-05-17 |
Intrexon Corporation |
Frataxin expression constructs
|
IL303108B1
(en)
|
2017-01-31 |
2024-03-01 |
Pfizer |
NEISSERIA MENINGITIDIS preparations and methods therefor
|
US11357856B2
(en)
|
2017-04-13 |
2022-06-14 |
Acuitas Therapeutics, Inc. |
Lipids for delivery of active agents
|
JP7297676B2
(ja)
|
2017-04-28 |
2023-06-26 |
アクイタス セラピューティクス インコーポレイテッド |
新規なカルボニル脂質、および核酸を送達するための脂質ナノ粒子製剤
|
JP7355731B2
(ja)
|
2017-08-16 |
2023-10-03 |
アクイタス セラピューティクス インコーポレイテッド |
脂質ナノ粒子製剤における使用のための脂質
|
WO2019036028A1
(en)
|
2017-08-17 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS
|
WO2019036030A1
(en)
|
2017-08-17 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS
|
EP3539975A1
(en)
|
2018-03-15 |
2019-09-18 |
Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron |
Micropeptides and uses thereof
|
EP3835320A4
(en)
|
2018-08-10 |
2022-06-01 |
Eutilex Co., Ltd. |
BINDING OF CHEMERA ANTIGEN RECEPTOR TO HLA-DR, AND CAR-T CELL
|
CN113474328A
(zh)
|
2019-01-11 |
2021-10-01 |
爱康泰生治疗公司 |
用于脂质纳米颗粒递送活性剂的脂质
|
CN114174327A
(zh)
|
2019-03-08 |
2022-03-11 |
黑曜石疗法公司 |
用于可调整调控的cd40l组合物和方法
|
IL294327A
(en)
*
|
2020-01-03 |
2022-08-01 |
Ascendis Pharma As |
Conjugates undergoing intramolecular rearrangements
|
JP2023509770A
(ja)
|
2020-01-08 |
2023-03-09 |
オブシディアン セラピューティクス, インコーポレイテッド |
転写の調節可能な制御のための組成物及び方法
|
EP3885440A1
(en)
|
2020-03-26 |
2021-09-29 |
Splicebio, S.L. |
Split inteins and their uses
|
US11976019B2
(en)
|
2020-07-16 |
2024-05-07 |
Acuitas Therapeutics, Inc. |
Cationic lipids for use in lipid nanoparticles
|